Latest / Community Health Media
Dr. Ursa Brown Glaberman & Dr. Karthik Giridhar- Managing Capiva-sertib & the AKT Path-way in 2L mBC
How are we navigating the evolving landscape of second-line treatment for metastatic HR-positive, HER2-negative breast cancer?
In this full-length discussion, Dr. Ursa Brown-Glaberman and Dr. Karthik Giridhar explore one of the most rapidly evolving areas in breast oncology: treatment selection after progression on first-line endocrine therapy and CDK4/6 inhibitors.
The conversation examines how molecular profiling, ctDNA testing, AKT pathway targeting,PIK3CA alterations, ESR1 mutations, and emerging biomarkers are reshaping decision-making in the second-line setting. The experts also discuss…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.